Ubs Group Ag Passage Bio, Inc. Transaction History

Ubs Group Ag

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.79 - $1.58 $905 - $1,810	1,146 New	1,146 $0
Q4 2023 Feb 09, 2024	BUY	$0.6 - $1.01 $635 - $1,069	1,059 New	1,059 $1,000
Q4 2022 Feb 08, 2023	SELL	$1.06 - $1.48 $10,693 - $14,930	-10,088 Reduced 85.14%	1,761 $2,000
Q3 2022 Nov 10, 2022	BUY	$1.22 - $2.48 $14,455 - $29,385	11,849 New	11,849 $15,000
Q2 2022 Aug 10, 2022	SELL	$1.63 - $3.46 $2,244 - $4,764	-1,377 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.66 - $6.49 $52,524 - $128,151	-19,746 Reduced 93.48%	1,377 $4,000
Q4 2021 Feb 14, 2022	BUY	$6.24 - $10.2 $125,124 - $204,530	20,052 Added 1872.27%	21,123 $134,000
Q3 2021 Nov 15, 2021	SELL	$9.73 - $15.52 $64,402 - $102,726	-6,619 Reduced 86.07%	1,071 $11,000
Q2 2021 Aug 13, 2021	SELL	$12.44 - $19.45 $420,148 - $656,904	-33,774 Reduced 81.45%	7,690 $102,000
Q1 2021 May 12, 2021	BUY	$16.24 - $29.83 $642,227 - $1.18 Million	39,546 Added 2061.84%	41,464 $725,000
Q4 2020 Feb 11, 2021	BUY	$14.28 - $29.73 $27,389 - $57,022	1,918 New	1,918 $49,000
Q3 2020 Nov 12, 2020	SELL	$12.39 - $26.15 $57,155 - $120,629	-4,613 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$14.59 - $36.07 $67,303 - $166,390	4,613 New	4,613 $126,000

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $31.6M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.